These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 39087451

  • 1. Novel Inhibition of Central Carbon Metabolism Pathways by Rac and CDC42 inhibitor MBQ167 and Paclitaxel.
    Cruz-Collazo AM, Katsara O, Grafals-Ruiz N, Colon Gonzalez J, Dorta-Estremera S, Carlo VP, Chorna N, Schneider RJ, Dharmawardhane S.
    Mol Cancer Ther; 2024 Nov 04; 23(11):1613-1625. PubMed ID: 39087451
    [Abstract] [Full Text] [Related]

  • 2. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D, Zhang B, Fan C, Mo C, Lee BH, Wei K.
    Cells; 2019 Aug 14; 8(8):. PubMed ID: 31416135
    [Abstract] [Full Text] [Related]

  • 3. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
    Wu Q, Ma X, Jin Z, Ni R, Pan Y, Yang G.
    J Ethnopharmacol; 2023 Oct 28; 315():116644. PubMed ID: 37196814
    [Abstract] [Full Text] [Related]

  • 4. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 5. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L.
    J Exp Clin Cancer Res; 2020 Sep 07; 39(1):180. PubMed ID: 32892748
    [Abstract] [Full Text] [Related]

  • 6. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
    Eiro N, Fraile M, Escudero-Cernuda S, Sendon-Lago J, Gonzalez LO, Fernandez-Sánchez ML, Vizoso FJ.
    Stem Cell Res Ther; 2024 Apr 25; 15(1):121. PubMed ID: 38664697
    [Abstract] [Full Text] [Related]

  • 7. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K, Le A, Weaver VM, Werb Z.
    Oncotarget; 2016 Dec 13; 7(50):82889-82901. PubMed ID: 27756881
    [Abstract] [Full Text] [Related]

  • 8. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA, Cole MW, Schafer RE, Spehar JM, Richardson DS, Steck SA, Das M, Lian AW, Ray A, Shakya R, Knoblaugh SE, Timmers CD, Ostrowski MC, Chakravarti A, Sizemore GM, Sizemore ST.
    Breast Cancer Res; 2021 Jun 12; 23(1):65. PubMed ID: 34118960
    [Abstract] [Full Text] [Related]

  • 9. IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.
    Wu M, Zhang L, Pi L, Liu L, Wang S, Wu Y, Pan H, Liu M, Yi Z.
    Cell Oncol (Dordr); 2024 Oct 12; 47(5):1797-1809. PubMed ID: 38888849
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X.
    Oncotarget; 2015 Aug 21; 6(24):20070-83. PubMed ID: 26036638
    [Abstract] [Full Text] [Related]

  • 11. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y, Xie D, Chen Z, Shen X, Wu X, Ding F, Ding S, Pan Y, Li F, Lu A, Zhang G.
    J Transl Med; 2024 Jul 01; 22(1):604. PubMed ID: 38951906
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer.
    Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hernández-O'Farrill E, Vlaar CP, Dharmawardhane S.
    Mol Cancer Ther; 2021 Dec 01; 20(12):2420-2432. PubMed ID: 34607932
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
    Martin JL, Julovi SM, Lin MZ, de Silva HC, Boyle FM, Baxter RC.
    Breast Cancer Res; 2017 Aug 04; 19(1):90. PubMed ID: 28778177
    [Abstract] [Full Text] [Related]

  • 14. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, Carrier L, Bu Y, Hangauer D, Rowan BG.
    Mol Cancer Ther; 2012 Sep 04; 11(9):1936-47. PubMed ID: 22784709
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS.
    J Exp Clin Cancer Res; 2019 Jan 11; 38(1):16. PubMed ID: 30635009
    [Abstract] [Full Text] [Related]

  • 16. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Pitts TM, Pelanda R, Eckhardt SG, Diamond JR.
    BMC Cancer; 2020 Nov 04; 20(1):1063. PubMed ID: 33148223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.